Long non-coding RNA ANRIL serves as a potential marker of disease risk, inflammation, and disease activity of pediatric inflammatory bowel disease - 28/05/22
, Yuanyuan He a, Qingguo Ren a, Simei Qin cHighlights |
• | Lnc-ANRIL expression correlates with pediatric IBD risk. |
• | Lnc-ANRIL expression correlates with active disease status of pediatric IBD. |
• | Lnc-ANRIL expression negatively correlates with inflammation in active pediatric IBD patients. |
• | Lnc-ANRIL expression negatively correlates with CDAI score in active pediatric CD patients. |
• | Lnc-ANRIL expression negatively correlates with mayo score in active pediatric UC patients. |
Abstract |
Background |
Long non-coding antisense RNAs in the INK4 locus (lnc-ANRIL) have been reported to be involved in inflammation and immunity. However, few studies have reported its clinical application in pediatric inflammatory bowel disease (IBD). Therefore, we conducted this study to investigate the correlation between lnc-ANRIL expression and disease risk, inflammation, and activity in pediatric IBD patients.
Methods |
Pediatric patients with Crohn's disease (CD; n = 40), ulcerative colitis (UC; n = 40), and controls (n = 20) were recruited. For all pediatric IBD patients, lnc-ANRIL expression in peripheral blood mononuclear cells and serum inflammatory cytokine levels were measured by RT-qPCR and ELISA, respectively. For the controls, lnc-ANRIL expression was also measured.
Results |
Lnc-ANRIL levels were lower in CD (P = 0.002) and UC (P = 0.001) patients compared with the controls; negatively correlated with C-reactive protein levels (P<0.01), erythrocyte sedimentation rate (P<0.01), disease activity (P<0.05), and severity (P<0.05) in CD and UC patients; and inversely associated with tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-17, and IL-23 levels in both CD and UC patients (all P<0.01). Further subgroup analyses revealed that the association between lnc-ANRIL and inflammatory cytokines and disease activity was more remarkable in pediatric patients with moderate or severe IBD.
Conclusion |
Lnc-ANRIL may serve as a potential marker for evaluating disease risk and monitoring disease activity in pediatric IBD patients.
Le texte complet de cet article est disponible en PDF.Keywords : Crohn's disease, Ulcerative colitis, lnc-ANRIL, Disease activity, Inflammatory cytokines
Plan
Vol 46 - N° 4
Article 101895- avril 2022 Retour au numéro
Article précédent
- Infectious complications of portal biliopathy leading to liver transplantation
- Thomas Levi-Strauss, Geoffroy Vanbiervliet, Patrick Chevallier, Rodolphe Anty, Albert Tran, Dann Joseph Ouizeman
- Complete endoscopic healing is associated with lower disability than partial endoscopic healing in Crohn's disease: A prospective multicenter study
- Clara Yzet, Franck Brazier, Virginie Sebbagh, Pierre Vanelslander, Valérie Dejour, Blanche David, Eric Nguyen-Khac, Momar Diouf, Mathurin Fumery
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?